Medtronic PLC vs VanEck Rare Earth/Strategic Metals — how do they compare? Medtronic PLC trades at $88.46 (market cap $112.24B), while VanEck Rare Earth/Strategic Metals trades at $60.83 (market cap $1.75B). The key difference: Medtronic PLC is far larger — about 64.1× VanEck Rare Earth/Strategic Metals's market cap, and Medtronic PLC pays a 3.28% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| MDT | REMX | |
|---|---|---|
Market Cap | $112.24B | $1.75B |
Volume | 105,663,236 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $105.35 | $109.53 |
52-Week Low | $73.75 | $60.58 |
Typical Hold Time | 63 Days | 50 Days |
Enterprise Value | $131.58B | — |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $61.88, down 2.99% with bearish technical signals dominating. The ETF faces pressure from rare earth sector volatility and mixed performance among constituent companies. Technical indicators show oversold conditions with RSI readings below 23, while ADX signals strong bearish momentum. Recent news highlights sector challenges including China's export controls and shifting trade policies affecting critical minerals.
The rare earth sector faces structural headwinds despite strategic importance. While U.S. supply chain development offers long-term potential, high volatility (~50% annualized) and China concentration pose significant risks. Current technical weakness suggests cautious approach until fundamental catalysts emerge from constituent company developments or policy shifts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →